|
Mapi Values has set up two advisory boards of health economic academic experts and reimbursement decision makers to complement their market access services. Mapi Values and the advisory boards work together to provide a unique service. This partnership results in an offering of creative, pragmatic and forward-thinking solutions to methodological thinking and reimbursement issues across key markets. Meetings are held with both advisory boards once every nine months to discuss current Health Technology Assessment (HTA) & Pricing & Reimbursement (P&R) issues. Advisory board members also provide ongoing consultation on Mapi Values’ projects.
Health Technology Assessment (HTA) Advisory Board
A board of academic experts, with expertise in epidemiology, evidence synthesis methods, utility assessment, and health economic evaluation help Mapi Values to use innovative, state-of-the-art and fit-for-purpose methods in their HTA related projects. These experts can review meta-analyses, health economic models, and reimbursement dossiers before submission, among others.
|
HTA Advisory Board Members |
Prof. Tony Ades, PhD.
University of Bristol, UK
Professor of Public Health Science.
Member of the Appraisal Committee at the National
Institute for Clinical Excellence (NICE).Jan van Busschbach, PhD.
Erasmus University, Rotterdam, Netherlands
Associated professor at the Department
for Medical Psychology. |
Prof. Dr. Maarten Boers, M.D., PhD.
VU University medical centre of Amsterdam, Netherlands
Clinical epidemiologist and rheumatologist.
Prof. Karl Claxton, DPhil, MSc.
University of York, UK
Senior Lecturer in the Department of Economics and Related Studies, University of York; Senior Research Fellow in the Centre for Health Economics, University of York, UK. Professor in the Department of Economics and Related Studies, Reviewer for NICE Appraisal Committee.
|
Pricing and Reimbursement (P&R) Advisory Board
Mapi Values has installed a Pricing and Reimbursement Advisory Board covering the major European markets and USA. This complements Mapi Values’ existing internal expertise of working in close collaboration with local HTA bodies. We work with the advisory board members as local experts, to keep abreast of trends and changes in healthcare systems, health and drug policies, and gain insights into the local decision-making processes.
|
P&R Advisory Board Members |
Bernard Avouac, MD
Hopital Henri Mondor, Paris, France
Member of the French Rheumatology Society, the Therapeutic Society, a founding member of the Osteo-arthritis Research Society, and a member of the American College of Rheumatology.Prof. Fernando Antoñanzas, PhD.
University of La Rioja, Spain
Professor in Health Economics.
Dr. Claudio Cricelli, M.D., PhD.
Florence Medical College, Italy
President of the Italian Association of General Practitioners (SIMG)
Past-President of European Union of General Practitioners (UEMO).
Prof. Reiner Leidl, PhD.
Ludwig-Maximillians University, Munich School of Management, Germany
Professor of Health Economics and Health Care Management GSF Research Center for Environment and Health Institute of Health Economics and Health Care Management. |
Keith Tolley, MPhil.
Economics Assessor on the evidence review board
of the Scottish Medicines Consortium (SMC).Prof. Stan Finkelstein, PhD.
Senior Research Scientist at the MIT and Co-Director of the Program on the Pharmaceutical Industry (POPI)
Senior Lecturer in the Department of Health Care Policy at Harvard Medical School and a member of the faculty of the Harvard-MIT Division of Health Sciences & Technology (HST) and the MIT Engineering Systems Division (ESD).
Prof. Maarten Postma, PhD.
University of Groningen, Netherlands
Professor at the department Social Pharmacy and
Pharmacoepidemiology, member of the Dutch Committee on Pharmaceutical Aid and the Health Council. Chair in
Pharmacoeconomics, pharmacotherapy, epidemiology & economics. |
|
PRO OFFERINGS
EMAIL / 
PRINT / 
SHARE